Lab
True Health Diagnostics, LLC
True Health Diagnostics, LLC was paid $1.86M by Medicaid between Jan 2018 and Sep 2019, across 126 billing codes. Its largest line is 82664, — 5.2% of everything it billed.
33Billing provider infoTRUE HEALTH DIAGNOSTICS, LLC
FRISCO, TX 75034
FRISCO, TX 75034
33aNPI1619376316assigned 08/19/2014
33bProvider typeClinical Medical Laboratory
28Total paid$1.86M
24GClaims229,420
24DCodes billed126
24AFirst – last monthJan 2018 – Sep 2019
Compared with peers
Next to other Clinical Medical Laboratory providers in Texas
Rank by total paid#47 of 436
Median peer was paid$17K
This provider vs. median108×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 131,531 | $982K | |
| 2019 | 97,889 | $883K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 82664 | 5.2% | 6,385 | 6,036 | $97K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 4.4% | 7,114 | 6,753 | $82K |
| 80050 | General health panel | 4.3% | 4,411 | 4,080 | $81K |
| 83880 | 4.0% | 4,418 | 4,175 | $74K | |
| 83876 | 3.9% | 4,862 | 4,565 | $73K | |
| 82172 | 3.7% | 6,182 | 5,946 | $70K | |
| 83698 | 3.0% | 4,456 | 4,288 | $56K | |
| 83704 | 2.9% | 5,320 | 5,119 | $55K | |
| 83520 | 2.8% | 4,256 | 3,869 | $52K | |
| 81401 | 2.4% | 938 | 883 | $45K | |
| 82726 | 2.3% | 5,318 | 5,010 | $44K | |
| 82542 | 2.3% | 4,774 | 4,466 | $43K |
114 more codes
| 80061 | Lipid panel | 2.2% | 8,963 | $41K |
| 83090 | 2.1% | 4,776 | $40K | |
| 84681 | 2.1% | 3,701 | $38K | |
| 84206 | 2.0% | 3,535 | $38K | |
| 83921 | 2.0% | 3,774 | $37K | |
| 86141 | 1.9% | 5,718 | $36K | |
| 86341 | 1.9% | 3,142 | $35K | |
| 82607 | 1.8% | 4,886 | $34K | |
| 84481 | 1.8% | 4,067 | $33K | |
| 82725 | 1.7% | 4,400 | $32K | |
| 82670 | 1.7% | 2,726 | $31K | |
| 83525 | 1.7% | 5,875 | $31K | |
| 82728 | 1.6% | 4,169 | $30K | |
| 82610 | 1.5% | 4,450 | $29K | |
| 82777 | 1.5% | 3,248 | $27K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.4% | 7,087 | $27K |
| 84403 | 1.4% | 3,265 | $27K | |
| 82985 | 1.4% | 3,374 | $26K | |
| 82627 | 1.4% | 2,696 | $25K | |
| 83516 | 1.3% | 1,266 | $25K | |
| 84311 | 1.3% | 5,677 | $24K | |
| 85385 | 1.3% | 3,505 | $24K | |
| 81241 | 1.1% | 733 | $21K | |
| 82747 | <1% | 3,134 | $19K | |
| 84270 | <1% | 2,405 | $19K | |
| 81240 | <1% | 651 | $17K | |
| 84439 | <1% | 4,686 | $17K | |
| 84144 | <1% | 2,126 | $16K | |
| 83001 | <1% | 1,934 | $15K | |
| 83002 | <1% | 1,793 | $15K | |
| 83789 | <1% | 2,980 | $14K | |
| 84378 | <1% | 1,542 | $12K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,590 | $12K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,038 | $12K |
| 86376 | <1% | 2,348 | $12K | |
| 82533 | <1% | 1,708 | $11K | |
| 83540 | <1% | 3,091 | $11K | |
| 84482 | <1% | 1,550 | $11K | |
| 86800 | <1% | 1,947 | $11K | |
| 84550 | <1% | 4,793 | $10K | |
| 81291 | <1% | 1,038 | $10K | |
| 83970 | <1% | 533 | $10K | |
| 84207 | <1% | 409 | $9K | |
| 84146 | <1% | 796 | $8K | |
| 82679 | <1% | 732 | $8K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 71 | $7K |
| 84140 | <1% | 696 | $7K | |
| 83735 | <1% | 3,226 | $7K | |
| 84480 | <1% | 1,154 | $7K | |
| 80327 | <1% | 298 | $6K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 953 | $5K |
| 80053 | Comprehensive metabolic panel | <1% | 3,572 | $5K |
| 86038 | <1% | 851 | $5K | |
| 82642 | <1% | 339 | $5K | |
| 86003 | <1% | 220 | $5K | |
| 84153 | <1% | 634 | $4K | |
| 84446 | <1% | 838 | $4K | |
| 84305 | <1% | 342 | $4K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 30 | $3K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 868 | $3K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 3,054 | $3K |
| 83550 | <1% | 546 | $3K | |
| 84431 | <1% | 715 | $2K | |
| 86200 | <1% | 409 | $2K | |
| 84466 | <1% | 477 | $2K | |
| 81225 | <1% | 134 | $2K | |
| 86431 | <1% | 756 | $2K | |
| 82248 | <1% | 987 | $2K | |
| 82947 | <1% | 669 | $2K | |
| 83722 | <1% | 194 | $1K | |
| 82136 | <1% | 250 | $1K | |
| 85652 | <1% | 1,030 | $1K | |
| 82131 | <1% | 255 | $1K | |
| 85379 | <1% | 446 | $926.41 | |
| 84436 | <1% | 1,146 | $813.83 | |
| 82977 | <1% | 202 | $755.84 | |
| 81001 | <1% | 887 | $676.08 | |
| 82570 | <1% | 1,082 | $653.68 | |
| 86334 | <1% | 134 | $532.55 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 31 | $486.41 |
| 84100 | <1% | 171 | $444.38 | |
| 82785 | <1% | 75 | $313.74 | |
| 85014 | <1% | 230 | $303.57 | |
| 87486 | <1% | 30 | $256.85 | |
| 87581 | <1% | 30 | $256.85 | |
| 83690 | <1% | 54 | $196.82 | |
| 80354 | <1% | 156 | $148.04 | |
| 82043 | <1% | 141 | $136.90 | |
| 84630 | <1% | 12 | $134.73 | |
| 80360 | <1% | 156 | $130.94 | |
| 80366 | <1% | 154 | $130.94 | |
| 80355 | <1% | 156 | $109.47 | |
| 80074 | <1% | 14 | $105.04 | |
| 86803 | <1% | 264 | $91.10 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 17 | $47.94 |
| 82150 | <1% | 14 | $47.78 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 13 | $24.84 |
| 80349 | <1% | 28 | $23.04 | |
| 84460 | <1% | 28 | $22.73 | |
| 81003 | <1% | 14 | $18.14 | |
| 84134 | <1% | 38 | $12.47 | |
| 80363 | <1% | 156 | $3.82 | |
| 80372 | <1% | 142 | $2.12 | |
| 80365 | <1% | 27 | $2.12 | |
| 80370 | <1% | 143 | $2.12 | |
| 80337 | <1% | 143 | $2.12 | |
| 87390 | 0% | 13 | $0.00 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 0% | 35 | $0.00 |
| 86701 | 0% | 13 | $0.00 | |
| 86702 | 0% | 13 | $0.00 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 0% | 35 | $0.00 |
| 80364 | 0% | 31 | $0.00 | |
| 80348 | 0% | 46 | $0.00 | |
| 80346 | 0% | 41 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGROTTENTHALER, CHRISTOPHER (CEO)